Exchange: NASDAQ·Updated 07:48 PM EDT
ALT logo

ALT Altimmune Inc

$3.42
$0.19
(5.88%)
Today
Closed $3.42
$0.02
(0.58%)
After Hours
Reported EarningsAug 12
Mkt Cap$665.25M
Vol4.87M

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
64

Bullish Sentiment

How do you feel about ALT?

Advertisement|Remove ads.